Literature DB >> 20541011

Perlecan deficiency causes muscle hypertrophy, a decrease in myostatin expression, and changes in muscle fiber composition.

Zhuo Xu1, Naoki Ichikawa, Keisuke Kosaki, Yoshihiko Yamada, Takako Sasaki, Lynn Y Sakai, Hisashi Kurosawa, Nobutaka Hattori, Eri Arikawa-Hirasawa.   

Abstract

Perlecan is a component of the basement membrane that surrounds skeletal muscle. The aim of the present study is to identify the role of perlecan in skeletal muscle hypertrophy and myostatin signaling, with and without mechanical stress, using a mouse model (Hspg2(-/-)-Tg) deficient in skeletal muscle perlecan. We found that myosin heavy chain (MHC) type IIb fibers in the tibialis anterior (TA) muscle of Hspg2(-/-)-Tg mice had a significantly increased fiber cross-sectional area (CSA) compared to control (WT-Tg) mice. Hspg2(-/-)-Tg mice also had an increased number of type IIx fibers in the TA muscle. Myostatin and its type I receptor (ALK4) expression was substantially decreased in the Hspg2(-/-)-Tg TA muscle. Myostatin-induced Smad activation was also reduced in a culture of myotubes from the Hspg2(-/-)-Tg muscle, suggesting that myostatin expression and its signaling were decreased in the Hspg2(-/-)-Tg muscle. To examine the effects of mechanical overload or unload on fast and slow muscles in Hspg2(-/-)-Tg mice, we performed tenotomy of the plantaris (fast) muscle and the soleus (slow) muscle. Mechanical overload on the plantaris muscle of Hspg2(-/-)-Tg mice significantly increased wet weights compared to those of control mice, and unloaded plantaris muscles of Hspg2(-/-)-Tg mice caused less decrease in wet weights compared to those of control mice. The decrease in myostatin expression was significantly profound in the overloaded plantaris muscle of Hspg2(-/-)-Tg mice, compared with that of control mice. In contrast, overloading the soleus muscle caused no changes in either type of muscle. These results suggest that perlecan is critical for maintaining fast muscle mass and fiber composition, and for regulating myostatin signaling.
Copyright © 2010 International Society of Matrix Biology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541011      PMCID: PMC2939214          DOI: 10.1016/j.matbio.2010.06.001

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  35 in total

Review 1.  Controlling TGF-beta signaling.

Authors:  J Massagué; Y G Chen
Journal:  Genes Dev       Date:  2000-03-15       Impact factor: 11.361

2.  Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia).

Authors:  S Nicole; C S Davoine; H Topaloglu; L Cattolico; D Barral; P Beighton; C B Hamida; H Hammouda; C Cruaud; P S White; D Samson; J A Urtizberea; F Lehmann-Horn; J Weissenbach; F Hentati; B Fontaine
Journal:  Nat Genet       Date:  2000-12       Impact factor: 38.330

3.  Perlecan is essential for cartilage and cephalic development.

Authors:  E Arikawa-Hirasawa; H Watanabe; H Takami; J R Hassell; Y Yamada
Journal:  Nat Genet       Date:  1999-11       Impact factor: 38.330

4.  Regulation of myostatin activity and muscle growth.

Authors:  S J Lee; A C McPherron
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

5.  GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding.

Authors:  R S Thies; T Chen; M V Davies; K N Tomkinson; A A Pearson; Q A Shakey; N M Wolfman
Journal:  Growth Factors       Date:  2001       Impact factor: 2.511

Review 6.  Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer.

Authors:  Kunihiro Tsuchida; Masashi Nakatani; Akiyoshi Uezumi; Tatsuya Murakami; Xueling Cui
Journal:  Endocr J       Date:  2007-09-14       Impact factor: 2.349

7.  Identification of a novel pool of extracellular pro-myostatin in skeletal muscle.

Authors:  Sarah B Anderson; Alfred L Goldberg; Malcolm Whitman
Journal:  J Biol Chem       Date:  2008-01-06       Impact factor: 5.157

8.  Electrophysiological studies in a mouse model of Schwartz-Jampel syndrome demonstrate muscle fiber hyperactivity of peripheral nerve origin.

Authors:  Andoni Echaniz-Laguna; Frédérique Rene; Christophe Marcel; Marie Bangratz; Bertrand Fontaine; Jean-Philippe Loeffler; Sophie Nicole
Journal:  Muscle Nerve       Date:  2009-07       Impact factor: 3.217

9.  Evidence of a dosage effect and a physiological endplate acetylcholinesterase deficiency in the first mouse models mimicking Schwartz-Jampel syndrome neuromyotonia.

Authors:  Morgane Stum; Emmanuelle Girard; Marie Bangratz; Véronique Bernard; Marc Herbin; Alban Vignaud; Arnaud Ferry; Claire-Sophie Davoine; Andoni Echaniz-Laguna; Frédérique René; Christophe Marcel; Jordi Molgó; Bertrand Fontaine; Eric Krejci; Sophie Nicole
Journal:  Hum Mol Genet       Date:  2008-07-21       Impact factor: 6.150

10.  Perlecan maintains the integrity of cartilage and some basement membranes.

Authors:  M Costell; E Gustafsson; A Aszódi; M Mörgelin; W Bloch; E Hunziker; K Addicks; R Timpl; R Fässler
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

View more
  29 in total

1.  Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation.

Authors:  Muneaki Ishijima; Nobuharu Suzuki; Kentaro Hozumi; Tomoya Matsunobu; Keisuke Kosaki; Haruka Kaneko; John R Hassell; Eri Arikawa-Hirasawa; Yoshihiko Yamada
Journal:  Matrix Biol       Date:  2012-03-07       Impact factor: 11.583

Review 2.  Laminin-211 in skeletal muscle function.

Authors:  Johan Holmberg; Madeleine Durbeej
Journal:  Cell Adh Migr       Date:  2012-11-15       Impact factor: 3.405

Review 3.  Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.

Authors:  Mary C Farach-Carson; Curtis R Warren; Daniel A Harrington; Daniel D Carson
Journal:  Matrix Biol       Date:  2013-08-31       Impact factor: 11.583

4.  Gene expressions in cerebral palsy subjects reveal structural and functional changes in the gastrocnemius muscle that are closely associated with passive muscle stiffness.

Authors:  Jessica Pingel; Marie-Louise Kampmann; Jeppe Dyrberg Andersen; Christian Wong; Simon Døssing; Claus Børsting; Jens Bo Nielsen
Journal:  Cell Tissue Res       Date:  2021-01-30       Impact factor: 5.249

5.  Hic1 Defines Quiescent Mesenchymal Progenitor Subpopulations with Distinct Functions and Fates in Skeletal Muscle Regeneration.

Authors:  R Wilder Scott; Martin Arostegui; Ronen Schweitzer; Fabio M V Rossi; T Michael Underhill
Journal:  Cell Stem Cell       Date:  2019-12-05       Impact factor: 24.633

6.  Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability.

Authors:  Gerhard Sengle; Robert N Ono; Takako Sasaki; Lynn Y Sakai
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

7.  Perlecan is required for FGF-2 signaling in the neural stem cell niche.

Authors:  Aurelien Kerever; Frederic Mercier; Risa Nonaka; Susana de Vega; Yuka Oda; Bernard Zalc; Yohei Okada; Nobutaka Hattori; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Stem Cell Res       Date:  2013-12-28       Impact factor: 2.020

8.  Synovial perlecan is required for osteophyte formation in knee osteoarthritis.

Authors:  Haruka Kaneko; Muneaki Ishijima; Ippei Futami; Naoki Tomikawa-Ichikawa; Keisuke Kosaki; Ryo Sadatsuki; Yoshihiko Yamada; Hisashi Kurosawa; Kazuo Kaneko; Eri Arikawa-Hirasawa
Journal:  Matrix Biol       Date:  2013-01-20       Impact factor: 11.583

Review 9.  A current view of perlecan in physiology and pathology: A mosaic of functions.

Authors:  Maria A Gubbiotti; Thomas Neill; Renato V Iozzo
Journal:  Matrix Biol       Date:  2016-09-06       Impact factor: 11.583

Review 10.  Engineered matrices for skeletal muscle satellite cell engraftment and function.

Authors:  Woojin M Han; Young C Jang; Andrés J García
Journal:  Matrix Biol       Date:  2016-06-04       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.